[go: up one dir, main page]

BRPI0906245A2 - Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit - Google Patents

Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit

Info

Publication number
BRPI0906245A2
BRPI0906245A2 BRPI0906245-9A BRPI0906245A BRPI0906245A2 BR PI0906245 A2 BRPI0906245 A2 BR PI0906245A2 BR PI0906245 A BRPI0906245 A BR PI0906245A BR PI0906245 A2 BRPI0906245 A2 BR PI0906245A2
Authority
BR
Brazil
Prior art keywords
compound
disorder
psychotic
cognitive
kit
Prior art date
Application number
BRPI0906245-9A
Other languages
English (en)
Inventor
David T Hung
Andrew Asher Protter
Sarvajit Chakravarty
Rajendra Parasmal Jain
Original Assignee
Medivation Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medivation Technologies Inc filed Critical Medivation Technologies Inc
Publication of BRPI0906245A2 publication Critical patent/BRPI0906245A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0906245-9A 2008-03-24 2009-03-24 Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit BRPI0906245A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3905808P 2008-03-24 2008-03-24
US14505809P 2009-01-15 2009-01-15
PCT/US2009/038142 WO2009120720A1 (en) 2008-03-24 2009-03-24 Bridged heterocyclic compounds and methods of use

Publications (1)

Publication Number Publication Date
BRPI0906245A2 true BRPI0906245A2 (pt) 2015-06-30

Family

ID=40651664

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906245-9A BRPI0906245A2 (pt) 2008-03-24 2009-03-24 Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit

Country Status (12)

Country Link
US (4) US8546381B2 (pt)
EP (1) EP2274307B1 (pt)
JP (2) JP5586577B2 (pt)
CN (1) CN102046625B (pt)
AR (1) AR071284A1 (pt)
AU (1) AU2009228401B2 (pt)
BR (1) BRPI0906245A2 (pt)
CA (1) CA2718790A1 (pt)
CL (1) CL2009000725A1 (pt)
PE (1) PE20091820A1 (pt)
TW (1) TWI450900B (pt)
WO (1) WO2009120720A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AU2009228398B2 (en) 2008-03-24 2014-07-03 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
AU2009228401B2 (en) 2008-03-24 2014-10-30 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
PA8843701A1 (es) * 2008-09-29 2010-05-26 Abbott Lab Derivados de indolina y métodos para usarlos
US9625475B2 (en) 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
AU2009308708B2 (en) 2008-10-31 2015-11-19 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
BRPI0919948A2 (pt) 2008-10-31 2015-08-25 Madivation Technologies Inc Pirido[4,3-b]indois contendo porções rígidas
KR20110132564A (ko) * 2009-02-11 2011-12-08 선오비온 파마슈티컬스 인코포레이티드 히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법
CA2760541A1 (en) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido[4,3-b] indoles and methods of use
US8741919B2 (en) 2009-04-29 2014-06-03 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
WO2011031818A2 (en) * 2009-09-11 2011-03-17 Sepracor Inc. Histamine h3 inverse agonists and antagonists and methods of use thereof
EP2480081A4 (en) * 2009-09-23 2013-03-06 Medivation Technologies Inc Bridged heterocyclic compounds and methods for their use
CA2775133A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
CN102711468B (zh) * 2009-09-23 2014-07-09 梅迪维新技术公司 吡啶并[4,3-b]吲哚化合物及其使用方法
WO2011044134A1 (en) 2009-10-05 2011-04-14 Albany Molecular Research, Inc. Epiminocycloalkyl(b)indole derivatives as serotonin sub-type 6 (5-ht6) modulators and uses thereof
MX2012007031A (es) * 2009-12-17 2012-07-04 Abbott Lab Indoles e indolinas fusionadas al anillo amina de cabeza de puente utiles para tratar transtornos neurodegenerativos y neuropsiquiatricos.
WO2011084433A2 (en) * 2009-12-17 2011-07-14 Abbott Laboratories Aza-bridged ring-fused indoles and indolines
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9067949B2 (en) 2011-01-19 2015-06-30 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
AU2012219251B2 (en) 2011-02-18 2016-05-12 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
RU2490268C2 (ru) * 2011-11-10 2013-08-20 Федеральное Государственное Бюджетное Учреждение Науки Институт Физиологически Активных Веществ Российской Академии Наук (Ифав Ран) ХЛОРГИДРАТЫ ФТОРСОДЕРЖАЩИХ ЗАМЕЩЕННЫХ 5-[2-(ПИРИД-3-ИЛ)-ЭТИЛ]-2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛОВ, В КАЧЕСТВЕ СРЕДСТВ СНИЖЕНИЯ НЕКОНТРОЛИРУЕМОЙ АГРЕГАЦИИ БЕЛКОВ В НЕРВНОЙ СИСТЕМЕ, ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ИХ ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
EP2887804B1 (en) 2012-05-22 2021-01-27 Trustees of Dartmouth College Cycloalkanyl[b]indoles useful as glp-1 modulators

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360673A (en) * 1980-03-31 1982-11-23 Schering Corporation 5 Phenyl-1,3-alkano-1,2,3,4,4a,9b-hexahydropyrido [4,3-b]indoles
US5273977A (en) * 1990-11-05 1993-12-28 Warner-Lambert Company Substituted tetrahydropyridines and hydroxypiperidines as central nervous system agents
US5250537A (en) * 1992-03-13 1993-10-05 Scios Nova Inc. 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole,-6,7,8,9,10-hexahydro-7,11-imino-5H-cyclooct[b]indole and substituted derivatives
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера
US6251893B1 (en) * 1998-06-15 2001-06-26 Nps Allelix Corp. Bicyclic piperidine and piperazine compounds having 5-HT6 receptor affinity
US20040041081A1 (en) 2002-08-30 2004-03-04 Feldman Michael R. Integrated optical transceiver and related methods
WO2002037480A1 (fr) 2000-10-26 2002-05-10 Hitachi, Ltd. Curseur de tete magnetique et dispositif a disque magnetique
US20040077261A1 (en) 2002-02-11 2004-04-22 Fitzgerald David J. Children's toy waterslide
DE10325738B3 (de) 2003-06-06 2004-12-02 Atlas Elektronik Gmbh Verfahren zur Generierung eines dreidimensionalen Geländemodells
US7736889B2 (en) 2003-06-10 2010-06-15 The United States Of America As Represented By The Secretary Of The Navy Fluidic force discrimination
US20070179174A1 (en) 2003-12-08 2007-08-02 Bachurin Sergei O Methods and compositions for slowing aging
RU2283108C2 (ru) 2003-12-08 2006-09-10 Сергей Олегович Бачурин ГЕРОПРОТЕКТОР НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
DE102005017477A1 (de) 2005-02-18 2006-08-31 Tecpharma Licensing Ag Feder in einem oder für ein Injektionsgerät
JP4408842B2 (ja) 2005-06-30 2010-02-03 株式会社リコー シート搬送装置、自動原稿搬送装置、給紙装置および画像形成装置
KR100933426B1 (ko) 2005-07-21 2009-12-23 주식회사 엘지화학 가변성 전지 카트리지 및 그것으로 구성된 중대형 전지모듈
KR100806812B1 (ko) 2005-07-25 2008-02-25 엘지.필립스 엘시디 주식회사 유기 el 소자 및 그 제조방법
US20070022645A1 (en) 2005-07-29 2007-02-01 Villarin Luna H Magnetic display holder
US20070024626A1 (en) 2005-07-29 2007-02-01 Microsoft Corporation Large character set handling in limited devices
JP2009506988A (ja) 2005-08-19 2009-02-19 エラン ファーマシューティカルズ,インコーポレイテッド ガンマセクレターゼの架橋n−環状スルホンアミド阻害剤
EP1937263A2 (en) 2005-10-04 2008-07-02 Medivation, Inc. Hydrogenated pyrido-indole compounds for the treatment of huntington ' s disease
RU2338537C2 (ru) 2006-01-25 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
US7768963B2 (en) 2006-07-07 2010-08-03 Skyhook Wireless, Inc. System and method of improving sampling of WLAN packet information to improve estimates of Doppler frequency of a WLAN positioning device
DE102006031693A1 (de) 2006-07-08 2008-01-17 Magna Car Top Systems Gmbh Tragvorrichtung für ein Fahrrad
JP2010504337A (ja) 2006-09-20 2010-02-12 メディベイション ニューロロジー, インコーポレイテッド イヌの認知機能障害症候群の治療のためのディメボン(dimebon)などの水素化ピリド[4,3−b]インドール
CA2664099A1 (en) 2006-09-20 2008-03-27 Medivation Neurology, Inc. Methods and compositions for treating amyotrophic lateral sclerosis (als)
JP2010507672A (ja) 2006-10-27 2010-03-11 メディベイション ニューロロジー, インコーポレイテッド アルツハイマー病を治療するための方法および組み合わせ治療
RU2329044C1 (ru) 2006-11-16 2008-07-20 Андрей Александрович Иващенко Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство
RU2334514C1 (ru) 2006-12-01 2008-09-27 Институт физиологически активных веществ Российской Академии наук СРЕДСТВО ДЛЯ УЛУЧШЕНИЯ КОГНИТИВНЫХ ФУНКЦИЙ И ПАМЯТИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО (4,3-b) ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2340342C2 (ru) 2006-12-07 2008-12-10 Сергей Олегович Бачурин СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ОСТРЫХ И ХРОНИЧЕСКИХ НАРУШЕНИЙ МОЗГОВОГО КРОВООБРАЩЕНИЯ, В ТОМ ЧИСЛЕ ИНСУЛЬТА, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО[4,3-b]ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
RU2338745C1 (ru) 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
RU2339637C1 (ru) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Блокаторы гистаминного рецептора для фармацевтических композиций, обладающих противоаллергическим и аутоиммунным действием
CA2683453C (en) 2007-04-05 2013-06-11 Alla Chem, Llc Substituted 2,3,4,5-tetrahydro-1h-pyrido[4,3-.beta.]indoles, methods for the production and use thereof
JP2010528016A (ja) 2007-05-25 2010-08-19 メディベーション ニューロロジー, インコーポレイテッド 細胞を刺激するための方法および組成物
RU2338533C1 (ru) 2007-06-28 2008-11-20 Сергей Олегович Бачурин СРЕДСТВО, ОБЛАДАЮЩЕЕ АНКСИОЛИТИЧЕСКИМ ДЕЙСТВИЕМ, НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ
WO2009017836A1 (en) 2007-08-01 2009-02-05 Medivation Neurology, Inc. Methods and compositions for treating schizophrenia using antipsychotic combination therapy
WO2009039420A1 (en) 2007-09-21 2009-03-26 Medivation Neurology, Inc. Methods and compositions for treating neuronal death mediated ocular diseases
RU2007139634A (ru) 2007-10-25 2009-04-27 Сергей Олегович Бачурин (RU) Новые тиазол-, триазол- или оксадиазол-содержащие тетрациклические соединения
JP2011507835A (ja) 2007-12-21 2011-03-10 アンドレイ・アレクサンドロビッチ・イワシェンコ α−アドレナリン受容体、ドーパミン、ヒスタミン、イミダゾリン及びセロトニン受容体のリガンド並びにその使用
RU2544856C2 (ru) 2008-01-25 2015-03-20 Сергей Олегович Бачурин НОВЫЕ ПРОИЗВОДНЫЕ 2,3,4,5-ТЕТРАГИДРО-1-ПИРИДО[4,3-b]ИНДОЛА И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
WO2009111540A1 (en) 2008-03-04 2009-09-11 Medivation Neurology, Inc. Methods for preparing pyridylethyl-substituted carbolines
AU2009228401B2 (en) 2008-03-24 2014-10-30 Medivation Technologies, Inc. Bridged heterocyclic compounds and methods of use
AU2009228398B2 (en) 2008-03-24 2014-07-03 Medivation Technologies, Inc. Pyrido [3, 4-b] indoles and methods of use
PT2260042E (pt) 2008-03-27 2011-12-06 Gruenenthal Gmbh Derivados de ciclo-hexano espirocíclicos substituídos
WO2009135091A1 (en) 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
WO2010014758A1 (en) 2008-07-30 2010-02-04 Edison Pharmaceuticals, Inc. Use of hydrogenated pyrido[4,3-b] indoles for the treatment of oxidative stress
PA8843701A1 (es) * 2008-09-29 2010-05-26 Abbott Lab Derivados de indolina y métodos para usarlos
US9625475B2 (en) * 2008-09-29 2017-04-18 Abbvie Inc. Indole and indoline derivatives and methods of use thereof
BRPI0919948A2 (pt) * 2008-10-31 2015-08-25 Madivation Technologies Inc Pirido[4,3-b]indois contendo porções rígidas
AU2009308708B2 (en) 2008-10-31 2015-11-19 Medivation Technologies, Inc. Azepino [4, 5-b] indoles and methods of use
US8362277B2 (en) 2009-01-09 2013-01-29 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
US9962368B2 (en) 2009-01-09 2018-05-08 Board Of Regents Of The University Of Texas System Pro-neurogenic compounds
BRPI1006825A2 (pt) 2009-01-09 2019-04-24 Univ Texas compostos pró-neurogênicos
US8741919B2 (en) * 2009-04-29 2014-06-03 Medivation Technologies, Inc. Pyrido[4,3-B]indoles and methods of use
CA2760541A1 (en) 2009-04-29 2010-11-04 Medivation Technologies, Inc. Pyrido[4,3-b] indoles and methods of use
WO2011014695A1 (en) 2009-07-29 2011-02-03 Medivation Technologies, Inc. New 2,3,4,5-tetrahydro-1h-pyrido[4,3-b] indoles and methods of use
CN102711468B (zh) 2009-09-23 2014-07-09 梅迪维新技术公司 吡啶并[4,3-b]吲哚化合物及其使用方法
EP2480081A4 (en) 2009-09-23 2013-03-06 Medivation Technologies Inc Bridged heterocyclic compounds and methods for their use
CA2775133A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
CA2775129A1 (en) 2009-09-23 2011-03-31 Medivation Technologies, Inc. Pyrido[3,4-b]indoles and methods of use
US20130172320A1 (en) 2010-02-18 2013-07-04 Sarvajit Chakravarty Pyrido [4,3-b] indole and pyrido [3,4-b] indole derivatives and methods of use
WO2011103485A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
US9034865B2 (en) 2010-02-18 2015-05-19 Medivation Technologies, Inc. Pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
US9193728B2 (en) 2010-02-18 2015-11-24 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
WO2011103430A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2011103448A1 (en) 2010-02-19 2011-08-25 Medivation Technologies, Inc. Methods and compositions for treating psychotic disorders using antipsychotic combination therapy
JP6126528B2 (ja) 2010-07-07 2017-05-10 ザ・ボード・オブ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・テキサス・システムThe Board Of Regents Of The University Of Texas System 神経新生促進化合物
US20140303144A1 (en) 2011-02-18 2014-10-09 Medivation Technologies, Inc. Compounds and methods of treating hypertension
AU2012219251B2 (en) 2011-02-18 2016-05-12 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112963A1 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. Compounds and methods for treatment of hypertension
WO2012112964A2 (en) 2011-02-18 2012-08-23 Medivation Technologies, Inc. PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE
WO2014031170A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
WO2014031165A1 (en) 2012-08-22 2014-02-27 Medivation Technologies, Inc. Compounds and methods of treating diabetes
CN108329253A (zh) 2012-08-24 2018-07-27 得克萨斯州大学系统董事会 前神经原性化合物

Also Published As

Publication number Publication date
JP5586577B2 (ja) 2014-09-10
US20130184269A1 (en) 2013-07-18
EP2274307A1 (en) 2011-01-19
US8999977B2 (en) 2015-04-07
US9051314B2 (en) 2015-06-09
HK1153196A1 (en) 2012-03-23
CL2009000725A1 (es) 2009-05-29
JP2014111655A (ja) 2014-06-19
US9034869B2 (en) 2015-05-19
HK1157751A1 (en) 2012-07-06
JP2011515483A (ja) 2011-05-19
CN102046625A (zh) 2011-05-04
TWI450900B (zh) 2014-09-01
PE20091820A1 (es) 2009-12-10
US20140024643A1 (en) 2014-01-23
US20130190303A1 (en) 2013-07-25
TW201000483A (en) 2010-01-01
US8546381B2 (en) 2013-10-01
AU2009228401B2 (en) 2014-10-30
WO2009120720A1 (en) 2009-10-01
AR071284A1 (es) 2010-06-09
CA2718790A1 (en) 2009-10-01
AU2009228401A1 (en) 2009-10-01
CN102046625B (zh) 2015-04-08
EP2274307B1 (en) 2015-07-29
US20100099667A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
BRPI0906244A2 (pt) Composto, composição farmacêutica, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissores ou um distúrbio neuronal em um indivíduo, uso de um composto e kit
BRPI0906245A2 (pt) Composto, método para tratar um distúrbio cognitivo, psicótico, mediado por neurotransmissor ou um distúrbio neuronal em indivíduo, uso de um composto, composição farmacêutica e kit
BRPI0816582A2 (pt) Composto, método para tratar um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou distúrbio neuronal em um indivíduo, composição farmacêutica, uso de um composto e kit
BR112012006646A2 (pt) composto, composição farmacêutica, método de tratamento de um distùrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit
BR112012006644A2 (pt) composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica, uso de um composto e kit
BR112012006640A2 (pt) composto, composição farmacêutica, método de tratamento de um distúrbio cognitivo, distúrbiopsocótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal e kit
BR112012006648A2 (pt) composto,método de tratamento de um distúrbio cognitivo, distúrbio psicótico, distúrbio mediado por neurotransmissor ou um distúrbio neuronal, composição farmacêutica e kit
BRPI0913585A2 (pt) composto, método para fabricar um composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios
BRPI0809655A2 (pt) Método para tratar uma condição em um mamífero, composição farmacêutica, e, kit
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
EP2271329A4 (en) METHOD, COMPOSITIONS AND SETS FOR TREATING PAIN AND PRURITIS
BRPI0919804A2 (pt) Métodos e composição para o tratemento de problemas dermatológicos e/ou condições de cabelo
BRPI0921687A2 (pt) Composto , conjugado , uso de um composto , composição farmacêutica, processo para preparar uma composição famacêutica , método para tratar um mamífero em necessidade do mesmo ,e, método para tratar ou prevenir um tumor em um mamífero.
BRPI0720604A8 (pt) composição e método para detecção de desmineralização
BRPI0921317A2 (pt) composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
BRPI0907977A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
BRPI0922475A2 (pt) composto, composição farmacêutica , método para tratar câncer, e, uso de um composto.
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BRPI0917458A2 (pt) composto, método de tratamento de doenças e condições, composição farmacêutica, método para tratar ou prevenir doença, e, uso de um composto
EP2295970A4 (en) IMMUNOTESTANALYZER AND IMMUNE TEST PROCEDURE
FI20070935L (fi) Koostumus ja menetelmä puun käsittelemiseksi
BRPI0811059A2 (pt) combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BRPI0913280A2 (pt) dispositivo e método para o tratamento de fluxos de artigos
BRPI0911098A2 (pt) formulação lipossomal e método para tratamento de bexiga hiperativa.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: MEDIVATION TECHNOLOGIES INC. (US)

B07D Technical examination (opinion) related to article 229 of industrial property law
B08F Application fees: dismissal - article 86 of industrial property law
B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)